Experimental Design: We assess three major subtype classifiers by meta-analysis of publicly available expression data, and assess statistical criteria of subtype robustness and classifier concordance. We develop a consensus classifier that represents the subtype classifications of tumors based on the consensus of multiple methods, and outputs a confidence score. Using our compendium of expression data, we examine the possibility that a subset of tumors are unclassifiable based on currently proposed subtypes.
Introduction
Ovarian carcinoma is a genomically complex disease, for which the accurate characterization of molecular subtypes is difficult but is anticipated to improve treatment and clinical outcome (1) .
Substantial effort has been devoted to characterize molecularly distinct subtypes of high-grade serous ovarian carcinoma (HGSOC) ( Table 1) . Initial large-scale efforts to classify HGSOC of the ovary did not reveal any reproducible subtypes (2) . Tothill et al (3) reported four distinct HGSOC subtypes: (i) an immunoreactive expression subtype associated with infiltration of immune cells, (ii) a low stromal expression subtype with high levels of circulating CA125, (iii) a poor prognosis subtype displaying strong stromal response, correlating with extensive desmoplasia, and (iv) a mesenchymal subtype with high expression of N/P-cadherins. The Cancer Genome Atlas (TCGA) project also identified four subtypes characterized by (i) chemokine expression in the immunoreactive subtype, (ii) proliferation marker expression in the proliferative subtype, (iii) ovarian tumor marker expression in the differentiated subtype, and (iv) expression of markers suggestive of increased stromal components in the mesenchymal subtype, but did not report differences in patient survival (4) . Further experimental characterization revealed an increased number of samples with infiltrating T lymphocytes for the immunoreactive subtype, whereas desmoplasia, associated with infiltrating stromal cells, was found more often for the mesenchymal subtype(5). Konecny et al.(6) , independently evaluated the TCGA subtypes and also reported the presence of the four transcriptional subtypes using a de novo clustering and classification method.
However, robustness and clinical relevance of these subtypes remain controversial (7) . The previous subtyping efforts have assessed prognostic significance in different patient cohorts, and have taken different approaches to validate these subtypes in independent datasets. A 5 recent review of HGSOC subtyping schemes highlighted the difficulty of comparing results of studies that used different subtyping algorithms, and that better general agreement on how molecular subtypes are defined would allow more widespread use of expression data in clinical trial design. (1) Assessing the generalizability of subtyping algorithms is challenging as true subtype classifications remain unknown. This challenge is evident in the lack of published validation of the proposed HGSOC subtypes. Subsequent efforts have performed de novo clustering of new datasets and noted similarity in the clusters identified, but they have not reported quantitative measures such as classification accuracy or rate of concordance with previously published algorithms (8) . In this article, we address these limitations by re-implementing three major subtyping methods (3, 5, 9) and assess between-classifier concordance and across-dataset robustness in a widely used database containing 1,770 HGSOC tumors(10), whose curation and data consistency has been independently validated (11) . We show that each pair of subtype classifiers are significantly concordant, and are virtually identical for tumors classified with high certainty. However, the subtypes do not meet established standards of robustness to reclustering (12) and only approximately one-third of tumors are classified concordantly by all three subtype classifiers. Using this core set of tumors concordantly classified by each method, we develop consensusOV, a consensus classifier that has high concordance with the three classifiers, therefore providing a standardized classification scheme for clinical applications.
Materials and Methods

Datasets
Analysis was carried out on datasets from the curatedOvarianData compendium; details of curation and of grading systems used by individual studies are described elsewhere (10).
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Datasets were additionally processed using the MetaGxOvarian package(13) (Supplementary Information). Analysis was restricted to datasets featuring microarray-based wholetranscriptome studies of at least 40 patients with late stage, high-grade, primary tumors of serous histology. This resulted in 15 microarray studies, providing data for 1,774 patients (Table   2 ). Duplicated samples identified by the doppelgangR package were removed (14) . Survival analysis was performed for 13 of these datasets, which included 1,581 patients with annotated time to death or last time of follow-up.
Implementation of Subtype Classifiers
Subtype classifiers were re-implemented in R(15) using original data as described by Konecny(6) , Verhaak(5) , and Helland (9) . These classifiers are based on nearest-centroids(6), subtype-specific single-sample GSEA(5), and subtype-specific linear coefficients(9), respectively. Implementations were validated by reproducing a result from each of the original publications (Supplemental File, Section 'Reproduction of Published HGSOC Subtype Classifiers').
Survival Analysis
Subtype calls from all included datasets were combined to generate a single Kaplan-Meier plot for each subtyping algorithm (stratified by subtype). Hazard ratios for overall survival between subtypes was estimated by Cox proportional hazards, and statistical significance was assessed by log-rank test using the survcomp R package (16) . Hazard ratios were calculated using the lowest-risk subtype as the baseline group, and stratification by dataset was performed for hazard ratios and significance testing.
Prediction Strength
Prediction Strength(12) is defined as a measure of the similarity between pairwise comemberships of a validation dataset from class labels assigned by (1) a clustering algorithm and (2) a classification algorithm trained on a training dataset (Supplementary Figure 1) . The quantity is an established measure of cluster robustness with the following interpretation: a value of 0 or below indicates poor concordance, and a value of 1 indicates perfect concordance between models specified from training and validation data. For each pair of subtype classifiers, classification concordance was assessed on both the full dataset and considering only patients classified with margins above a user-defined cutoff.
Building a consensus classifier
The consensusOV classifier was implemented using a Random Forest classifier trained on concordantly-subtyped tumors across multiple datasets. The Random Forest method has previously been used for building a multi-class consensus classifier to resolve inconsistencies among published colorectal cancer subtyping schemes (19) . In order to avoid normalizing expression values across datasets, binary gene pair vectors were used as feature space, as recently applied for breast cancer subtyping (20, 21) . To address differences in gene expression 
Leave-one-dataset-out cross-validation
Performance of the consensus classifier for identifying concordantly classified subtypes was assessed using leave-one-dataset-out cross-validation (22) . Concordant subtypes were identified to train the Random Forest classifier using 14 of the 15 datasets, and subtype predictions were tested in the remaining left-out dataset. This process was repeated for all 15
datasets. While predicting the samples in any given dataset, the training set was subsetted to contain only the concordant subtypes in other datasets.
Correlation analysis with Histopathology and Tumor Purity
Subtype calls from the Consensus Classifier were analysed for correlation with histopathology and tumor purity in the TCGA dataset. In order to best represent the most confident subtype calls, a default cutoff was used to include only the 25% of patients with the largest classification margins. Available histopathology variables included lymphocyte, monocyte, and neutrophil infiltration. Tumor purity was assessed using the ABSOLUTE algorithm(23), which estimates purity and ploidy from copy number and SNP allele frequency from SNP genotyping arrays (Synapse dataset syn3242754). Significance of associations were tested by one-way ANOVA for patient age, purity, and immune infiltration.
Research reproducibility
All results are reproducible using R/Bioconductor(24) and knitr (25) with LaTeX output at overleaf.com/read/srvqbpxpqbyz. Output of this code is provided as Supplemental File 1. 
Results
We performed a meta-analysis of three published subtyping algorithms for HGSOC (5, 6, 9) and developed a new consensus classifier to identify unambiguously classifiable tumors ( Table 1) .
Each of these algorithms identified four distinct HGSOC subtypes with specific clinical and tumor pathology characteristics ( Figure 1 ). We assessed the algorithms on a compendium of 15 datasets including over 1,700 HGSOC patients (Table 2 ) with respect to concordance, robustness, and association to patient outcome. By modifying individual algorithms to discard tumors of intermediate subtype, we found that concordance between algorithms is greatly improved.
Concordance of published classifiers
We reimplemented three published HGSOC subtype classifiers(5,6,9) ( Figure 2C ). This large gain in concordance results from large reductions in both singleton calls -tumors assigned to one subtype by one algorithm, but not by the other two algorithms -and in 2-to-1 calls, tumors assigned to one subtype by two algorithms, but not by the third ( Figure 2D ). This indicates that tumors distinctly classifiable by a single algorithm are more likely to be concordantly classified by the other algorithms, and conversely, tumors that appear ambiguous to one algorithm are less likely to be classified in the same way by the other algorithms.
Survival Analysis
All proposed subtyping algorithms classified patients into groups that significantly differed in overall survival ( Figure 3A , p < 10 -5 for each subtyping algorithm, log-rank test). Comparing lowrisk to high-risk subtypes for each algorithm, the hazard ratios increase from approximately 1.5 as marginal cases are removed ( Figure 3B ), suggesting that marginal cases may contribute to the intermediate survival profiles between subtypes.
Robustness of the Classifiers
Robust molecular subtyping should be replicable in multiple datasets. We performed de novo clustering in 15 independent ovarian datasets using the authors' original gene lists and clustering methods. We compared these de novo clusters to the labels from our implementation of the published classifiers to assess robustness using the Prediction Strength (PS) statistic (12) .
For PS estimation, we included validation datasets with at least 100 HGSOC tumors. Overall we observed low robustness for all classifiers, with PS values under 0.6 for the three algorithms across datasets (Supplementary Figure 2) , none meeting the 0.8 threshold typically indicating robust classes (12, 17) .
To assess whether low confidence predictions are driving the PS estimation, we re-computed the robustness of each algorithm set to classify varying fractions of the tumors with the highest margins. We used the largest dataset available, the TCGA dataset, as the validation set, and varied margin cutoffs of the Tothill and Konecny classifiers to require them to classify between 25% and 100% of the cases. From 10 random clustering runs, we report the median PS for the dataset. Clustering was performed on the full TCGA dataset and tumors of low margin values were removed subsequent to clustering and after the classifier was fully defined, in order to avoid optimistically biasing the apparent strength of clusters. We observed that the robustness of each algorithm is substantially improved by preventing them tto classify ambiguous cases.
The Tothill algorithm achieved almost perfect robustness (PS = 0.96) when allowed to leave 75% of cases unclassified ( Figure 4 ).
Consensus Classifier
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To maximize concordance across classifiers, we developed consensusOV, a consensus subtyping scheme facilitating classification of tumors of well-defined subtypes ( Figure 5 ). This classifier uses binary gene pairs (20, 21) to support application across gene expression platforms. The consensusOV classifier exhibits overall pairwise concordance of 67 -78% with each of the other three algorithms, when classifying all tumors; and 94% concordance with tumors that are concordantly classified by the other three algorithms ( Figure 5A ). The margins of consensusOV are higher for concordantly classified cases than for non-concordantly classified cases, and this difference in margins is greater than for any of the other three classifiers ( Figure 6A ). Accordingly, consensusOV was also most effective in identifying concordantly classified cases, although it was similar to the Konecny classifier in this respect (AUC = 0.76, Figure 6B ). As expected, differences in survival of subsets identified by consensusOV are similar to those identified by previous classifiers. The highest risk subtypes are proliferative (HR=1.44, 95% CI: 1.07−1.94) and mesenchymal (HR=1.97, 95% CI:
1.46−2.67) when removing 75% of indeterminate low-margin tumors, with similar hazard ratios for the concordant cases ( Figure 5B ).
Discussion
The existence of four distinct and concordant molecular subtypes of HGSOC has been reported in several studies of large patient cohorts(4-6,9), but also called into question by another effort(2) that could not identify subtypes, and by an independent validation effort that reported only two or three reproducible subtypes (27) . Meanwhile, significant effort is being expended to translate these subtypes to clinical practice, for example to predict response to the angiogenesis inhibitor bevacizumab in the ICON7 trial (28, 29) . Our study pursues three major objectives: (1) reproduction of published subtype classification algorithms as an open-source resource; (2) evaluation of the robustness and prognostic value of each proposed subtyping scheme in independent data; and (3) consolidation of proposed subtyping schemes into a consensus algorithm.
We find that while the proposed 4-subtype classifications demonstrate significant concordance and association with patient survival, none are robust to re-training in new datasets. By number deceased (median survival in months).
FIGURE CAPTIONS
Figure 1: Properties of Subtypes identified by Consensus Classifier. Subtype associations with patient age and overall survival were assessed across our compendium of microarray datasets; association with tumor purity and immune cell infiltration was assessed using the TCGA dataset. Tumor purity was estimated from genotyping data in TCGA; lymphocyte infiltration was based on pathology estimates from TCGA. Patient age (p < 0.001), overall survival (p < 0.005), and ABSOLUTE purity (p < 0.001) were statistically significant across subtypes. When compared to all other groups, the Immunoreactive subtype had elevated infiltration of lymphocytes (p < 0.05) and neutrophils (p < 0.10). Mean monocyte infiltration was less than 5% across all subtypes, and was excluded from this analysis. Classification was performed using default parameters, and mean values of each variable are shown. 
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